CN1060310A - 用于免疫诊断结核病的新的17KDa蛋白抗原及由其衍生的肽片段的制备方法 - Google Patents
用于免疫诊断结核病的新的17KDa蛋白抗原及由其衍生的肽片段的制备方法 Download PDFInfo
- Publication number
- CN1060310A CN1060310A CN91101235A CN91101235A CN1060310A CN 1060310 A CN1060310 A CN 1060310A CN 91101235 A CN91101235 A CN 91101235A CN 91101235 A CN91101235 A CN 91101235A CN 1060310 A CN1060310 A CN 1060310A
- Authority
- CN
- China
- Prior art keywords
- peptide
- tuberculosis
- albumen
- 17kda
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 51
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- 241000186359 Mycobacterium Species 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 210000004910 pleural fluid Anatomy 0.000 claims description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 8
- 208000026435 phlegm Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 50
- 108091007433 antigens Proteins 0.000 abstract description 50
- 102000036639 antigens Human genes 0.000 abstract description 50
- 150000001413 amino acids Chemical class 0.000 abstract description 14
- 238000000926 separation method Methods 0.000 abstract description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000012163 sequencing technique Methods 0.000 abstract description 2
- 230000000984 immunochemical effect Effects 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000000527 lymphocytic effect Effects 0.000 description 6
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 5
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 5
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 5
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960002109 tuberculosis vaccine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000187481 Mycobacterium phlei Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001595482 Columbicola bacillus Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- JFUIHGAGFMFNRD-UHFFFAOYSA-N fica Chemical compound FC1=CC=C2NC(C(=O)NCCS)=CC2=C1 JFUIHGAGFMFNRD-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9001105A SE9001105D0 (sv) | 1990-03-27 | 1990-03-27 | New methods foer diagnosis of tuberculosis |
SE9001105 | 1990-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1060310A true CN1060310A (zh) | 1992-04-15 |
Family
ID=20379003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91101235A Pending CN1060310A (zh) | 1990-03-27 | 1991-03-27 | 用于免疫诊断结核病的新的17KDa蛋白抗原及由其衍生的肽片段的制备方法 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0479971A1 (pt) |
CN (1) | CN1060310A (pt) |
AU (1) | AU7564491A (pt) |
BR (1) | BR9105237A (pt) |
IL (1) | IL97572A0 (pt) |
JO (1) | JO1671B1 (pt) |
PT (1) | PT97150A (pt) |
SE (1) | SE9001105D0 (pt) |
WO (1) | WO1991014448A1 (pt) |
ZA (1) | ZA911855B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
DE69435138D1 (de) | 1993-11-23 | 2008-10-23 | Univ California | Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung |
US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
CN103063836B (zh) * | 2011-10-18 | 2016-03-30 | 复旦大学附属华山医院 | 检测分枝杆菌感染的试剂、方法和试剂盒 |
CN111518165B (zh) * | 2020-05-08 | 2021-10-01 | 宁夏大学 | 一种特异性结合结核分枝杆菌的多肽、其编码基因及应用 |
CN112125954B (zh) * | 2020-09-28 | 2023-02-28 | 宁夏医科大学总医院 | 特异结合卡介苗bcg的七肽、编码基因、制备方法及用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345299A1 (en) * | 1987-02-02 | 1989-12-13 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
US4952395A (en) * | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
-
1990
- 1990-03-27 SE SE9001105A patent/SE9001105D0/xx unknown
-
1991
- 1991-03-13 ZA ZA911855A patent/ZA911855B/xx unknown
- 1991-03-15 IL IL97572A patent/IL97572A0/xx unknown
- 1991-03-21 JO JO19911671A patent/JO1671B1/en active
- 1991-03-22 AU AU75644/91A patent/AU7564491A/en not_active Abandoned
- 1991-03-22 WO PCT/SE1991/000225 patent/WO1991014448A1/en not_active Application Discontinuation
- 1991-03-22 EP EP91906940A patent/EP0479971A1/en not_active Withdrawn
- 1991-03-22 BR BR919105237A patent/BR9105237A/pt unknown
- 1991-03-26 PT PT97150A patent/PT97150A/pt not_active Application Discontinuation
- 1991-03-27 CN CN91101235A patent/CN1060310A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU7564491A (en) | 1991-10-21 |
JO1671B1 (en) | 1992-08-09 |
PT97150A (pt) | 1991-12-31 |
BR9105237A (pt) | 1992-07-21 |
ZA911855B (en) | 1991-12-24 |
SE9001105D0 (sv) | 1990-03-27 |
WO1991014448A1 (en) | 1991-10-03 |
IL97572A0 (en) | 1992-06-21 |
EP0479971A1 (en) | 1992-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Haas et al. | Immunoproteomics of Helicobacter pylori infection and relation to gastric disease | |
CN1151170C (zh) | Mage肿瘤排斥抗原前体衍生的与hla-a2分子形成复合物的分离肽 | |
Dechamma et al. | Identification of T-helper and linear B epitope in the hypervariable region of nucleocapsid protein of PPRV and its use in the development of specific antibodies to detect viral antigen | |
CN102124029A (zh) | 诊断由分枝杆菌引起的感染的方法和针对其的试剂 | |
CN1761682A (zh) | 单克隆抗体与产生该单克隆抗体的杂交瘤 | |
CN1060310A (zh) | 用于免疫诊断结核病的新的17KDa蛋白抗原及由其衍生的肽片段的制备方法 | |
CN1625565A (zh) | 非功能性p2x7受体的抗体,癌症及其它疾病的诊断和治疗 | |
CA2391356A1 (en) | Peptides designed for the diagnosis and treatment of rheumatoid arthritis | |
JP5709108B2 (ja) | XAGE−1b特異的免疫反応を誘導するペプチドおよびその利用 | |
US20130251749A1 (en) | Methods and compositions for chlamydial antigens as reagents/strategies for diagnosis and treatment of chlamydial infection and disease | |
CN1932517A (zh) | 检测或确定hcv核心抗原的方法及其中应用的用于检测或确定的试剂 | |
CN104105710A (zh) | 抗-spla2-v抗体以及其用途 | |
CN1687134A (zh) | 幽门螺杆菌HpaA和ureB单克隆抗体、免疫测定法和诊断试剂盒 | |
CN101580545B (zh) | 抗h5n1来源的血凝素蛋白的单克隆抗体及其应用 | |
KR20180124584A (ko) | 재조합 n 단백질에 대한 단클론항체를 이용한 아까바네바이러스 블러킹 효소결합면역측정법 | |
CN115980345A (zh) | 一种检测幽门螺旋杆菌的方法与应用 | |
US9068993B2 (en) | Diagnostic assays and methods of use for detection of filarial infection | |
KR20060129229A (ko) | 표면에 위치한 빈창자캄필로박터 폴리펩티드 | |
CN1645145A (zh) | 检测白念珠菌菌丝蛋白抗体的方法及试剂盒 | |
IE904536A1 (en) | New methods for diagnosis of tuberculosis | |
CN104628834B (zh) | 一种结核感染t细胞免疫检测抗原及其应用 | |
CN1429845A (zh) | 鼠抗氯霉素单克隆抗体及其用途 | |
McHugh et al. | The detection of bornavirus in birds, mammals and snakes by sandwich ELISA of bornaviral matrix protein | |
JPS60156383A (ja) | 膣トリコモナス決定因子に対して向けられたモノクロ−ナル抗体を産生するハイブリツド細胞系統 | |
KR101779443B1 (ko) | 브루셀라병 진단용 형광면역진단키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |